Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation

Exclusion Criteria

• •Suspected secondary cause for the ICH, such as an underlying vascular malformation (cavernous malformation, arteriovenous malformation, etc.), aneurysm, neoplasm, hemorrhagic transformation of an underlying ischemic infarct; or venous infarct Infratentorial or thalamic hemorrhage
• •Midbrain extension/involvement
• •Coagulopathy defined as international normalized ratio (INR) \> 1.4
• •Elevated activated Partial Thromboplastin Time (aPTT) \> 40 s
• •Concurrent use of direct oral anticoagulants or low molecular weight heparin at ICH onset
• •Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency
• •Platelet count \<100 x 103 cells/mm3, or known platelet dysfunction (reversal of coagulopathy is not allowed) GCS score \<7 at presentation
• •Evidence of active infection indicated by fever ≥100.7 °F and/or open draining wound at the time of enrollment
• •Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 365 days
• •Intraventricular extension of the hemorrhage is visually estimated to involve \> 50% of either of the lateral ventricles
• •Pregnancy (women of childbearing potential must have a negative pregnancy test to participate)
• •Based on investigator's judgment, the patient does not have the necessary mental capacity to participate or is unwilling to comply with the protocol follow-up schedule
• •Current participation in another interventional (drug or device) trial
• •Pre-existing Do Not Resuscitate (DNR)/Do Not Intubate (DNI) status
• •History of severe dementia